• Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Moran T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, TorresA, Camps C, Guijarro R, Isla D, Aguilo R, Alberola V, Padilla J, Sánchez-Palencia A, Sánchez JJ, Hermosilla E, Massuti B. Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, Vol 28, No 19 (July 1), 2010: pp. 3138-3145
  • Jantus-Lewintre E, Sanmartín E, Sirera R, Blasco A, Sanchez JJ, Tarón M, Rosell R, Camps C. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 2011 Nov;74(2):326-31.
  • Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki F, Wachters FM, Gebbia V, Tsai C-M, Camps C, Schuette W, Chiodini P, Piccirillo MC,Perrone F, Gallo C, Gridelli C. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. European Journal of Cancer European Journal of Cancer, 2009 Vol. 46, Issue 4, Pages 735-743
  • Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009 Sep 3;361(10):958-67. Epub 2009 Aug 19
  • Provencio M, de Las Peñas R, Camps C, Artal A, Massuti B, Cobo M, Pérez FJ, Sánchez A, Rosell. Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential? Lung Cancer 2010, 68 (3): 415-419 PubMed PMID: 19695734.
  • Rafael Rosell, Laia Perez-Roca, Jose Javier Sanchez, Manuel Cobo, Teresa Moran, Imane Chaib, Mariano Provencio, Manuel Domine, Maria Angeles Sala, Ulpiano Jimenez, Pilar Diz, Isidoro Barneto, Jose Antonio Macias, Ramon de las Peñas, Silvia Catot, Dolores Isla,Jose Miguel Sanchez, Rafael Ibeas, Guillermo Lopez-Vivanco, Juana Oramas, Pedro Mendez, Noemi Reguart, Remei Blanco, Miquel Taron. Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. PLoS One. 2009;4(5):e5133. Epub 2009 May 5.
  • Mariano Provencio, Carlos Camps, Vicente Alberola, Bartomeu Massuti, Nuria Viñolas Dolores Isla, Manuel Dómine, Isabel Millán, Manuel Cobo, Rafael Rosell. Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer. 2009 Oct;66(1):103-6.
  • Garrido P, Rosell R, Massutí B, Cardenal F, Alberola V, Dómine M, Maeztu I, Ramos A, Arellano A; Spanish Lung Cancer Group 0008 Investigators. Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clin Lung Cancer. 2009 May;10(3):180-6.
  • Vega Iranzo, Rafael Sirera, A. Carrato, Andrea Cabrera, Eloísa Jantus, Ricardo Guijarro, Elena Sanmartín, Ana Blasco, Mireia Gil, L. Gómez-Aldavarí, J.L.González-Larriba, B. Massuti, A. Velasco, M. Provencio, Rafael Rosell, Carlos Camps. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment of advanced non-small cell lung cancer (GECP 01-04). Clin Lung Cancer 2009 (submitted)
  • Bartolucci R, Wei J, Sánchez JJ, Pérez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, Taron M, Rosell R. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Clin Lung Cancer. 2009 Jan;10(1):47-52.
  • Sirera R, Gil M, Blasco A, Cabrera A, Safont MJ, Iranzo V, Cayuela D, Rosell R, Camps C. Retrospective analysis of the frequency of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer. Lung Cancer 2008 Jul;61(1):104-8
  • Safont MJ, Artal-Cortes A, Sirera R, Gómez-Codina J, González-Larriba JL, Barneto I, Carrato A, Isla D, Rosell R, Camps C. Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer. Lung Cancer. 2009 Jan;63(1):83-7. Epub 2008 Jun 13.
  • Skrzypski M, Jassem E, Taron M, Sanchez JJ, Mendez P, Rzyman W, Gulida G, Raz D, Jablons D, Provencio M, Massuti B, Chaib I, Perez-Roca L, Jassem J, Rosell R. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008 Aug 1;14(15):4794-9
  • Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, His P, Ding K, Waller D, Le Chevalier T on behalf of the LACE Collaborative Group. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. J Clin Oncol 2008 Jul 20;26(21):3552-9
  • Rosell R. Lung Cancer Genes. In response to “New treatments hope after lung cancer gene found” published in The Times Online, 3 April 2008.
  • Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, Stahel R, Trigo J, Wei J, Taron M. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small cell lung cancer. Clin Lung Cancer 2008, Vol 9 (Suppl 2): S76-S82
  • Molina MA, Bertran-Alamillo J, Reguart N, Taron M, Castella E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, , Botia M, Pérez-Cano M, Carrasco E, Tomas M, Mate J Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 1;14(17):5565-70
  • Gridelli C, Ardizzoni A, Ciardello F, Hanna N, Heymach J, Perrone F, Rosell R, Shephard FA, Thatcher N, Vansteenkiste J, De Petris L, Di Maio M, De Marinis F. Second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2008 Apr;3(4):430-40.
  • Douillard J-Y, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA. Impact of post operative radiation therapy (PORT) on survival in completely resected patients with stages I, II or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy in the randomized trial ANITA. Intl J Radiat Oncol Biol Phys 2008 Apr 24. (Epub ahead of print)
  • Garrido P, Massutí B, Cardenal F., Alberola V, Dómine M, Maeztu I, Arellano A, Ramos A, Rosell R (on behalf of the Spanish Lung Cancer Group 0008 investigators). Predictors of long-term survival in lung cancer patients included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy. Clinical Lung Cancer, Invited manuscript
  • L, Moran T and Rosell R. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thor Oncol 2008 , Vol 3, 11: 1224-1235
  • Rosell R , Vergnenegre A, Fournel P, Massuti B, Camps C , Isla D , Sanchez JM, Moran T, Sirera R and Taron M. Pharmacogenetics in lung cancer for the lay doctor. Targeted Oncology 2008 , Vol 3 (3): 161-171
  • Taron M, Molina MA, Mendez P, Sirera R, Camps C, Felip E, Massuti B, Carrasco E, Benlloch S, Ramon y Cajal S, Mate JL and Rosell R. The practicalities of pharmacogenomic Analysis- The Spanish Lung Cancer Group Experience. Le Nouveau Cancérologue 2008; 1: 1-3
  • Rosell R, and Garcia-Campelo, R. Farmacogenómica como instrumento de individualización del tratamiento del cáncer. Formación Médica Continuada en Oncología, Jun 2008 Vol 3, Suppl 1: 71-82
  • Perona R, Massuti B, Rosell R. Reflections on the IASLC 12th World Conference on Lung Cancer. Clin Transl Oncol 2008 Feb;10(2):67-9
  • Felip E, Rosell Permetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC).The Clin Risk Manag. 2008 Jun;4(3):579-85.
  • Garrido, JL González-Larriba, A. Insa, M. Provencio, A.Torres, D. Isla, JM. Sánchez, F. Cardenal, M. Domine, J.R Barcelo, V. Tarrazona, A. Varela, R. Aguilo, J. Astudillo, I.Muguruza, A. Artal, F. Hernando-Trancho, B. Massuti, M. Sanchez-Ronco, R. Rosell. Long-Term survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology. Vol. 25. No 30. : 4736-4742. October 20 2007
  • Rosell, M. Taron, JJ. Sánchez, L.Paz Ares. Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Medicine. Future Oncol. (2007) 3(3): 277-283
  • Cobo, D. Isla, B. Massuti, A. Montes, JM. Sanchez, M.Provencio, N.Viñolas, L. Paz-Ares, Guillermo Lopez-Vivanco, M.A. Muñoz, E. Felip, V. Alberola, C. Camps, M. Domine, J.J. Sanchez, M. Sanchez-Ronco, K. Danenberg, M.Taron, D. Gandara, R. Rosell. Customizing Cisplatin Base on Quatitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. Vol. 25. No 19: 2747-2754, July 1 2007
  • Rosell, M. Taron, N. Reguzrt, D. Isla, T. Moran. Epidermical Growth Factor Receptor ctivation: How Exon 19 and 21 Mutations Changed our Understanding of the Pathway. Clin Cancer Res 2006; 12 (24): 7222-7231 (Des. 15, 2006)
  • Rosell, M. Taron, M. Galvez, M.C. Pastor, C. Queralt, A. Pradas, M. Botia, M. Pérez, N. Reguart, T. Moran, J.M. Sánchez, M.L. Amador, J.L. Asensio, B. Massutí, L. Paz Ares en nombre del Grupo Español de Cáncer de Pulmón. Determinación de las mutaciones del receptor del factor de crecimiento epidérmico (EGFR) en pacientes con cáncer de pulmón no microcítico tratados únicamente con erlotinib. Formación Médica continuada Oncología. 2006
  • J-Y. Douillard, R. Rosell, M: de Lena, F. Carpagnano, R. Ramlau, J.L. González-Larriba, T. Grodzki, J. Rodrigues Pereira, A. Le Groumellec, V. Lorusso, C. Clary, A. J. Torres, J. Dahabreh, P.J, Souquet, J. Astudillo, P. Fournel, A. Artal, J. Jassem, L. Koubkova, P. His, M. Riggi, P. Hurteloup. Adjuvant Vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA NSCLC (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled The Lancet, Vol. 7: 719-727, sept 2006.
  • Rosell, M. Cobo, D. Isla, C. Camps, B. Massutí. Pharmacogenomics and gemcitabine. Annals of Oncology, 17, supplement 5): 13-16. may 2006
  • Rosell, M. Taron, N. Reguart, F. López-Ríos, L. Paz-Ares, J.L. Ramírez, B. Massutí, M. Cuello, D. Jablons, Pharmacogenomics comes of age in selecting patients for Lung Cancer Treatment. 2006 ASCO Educational Book
  • Rosell, M. Cuello, F. Ceccere, MC Santarpia, N. Reguart, E. Felip, M. Taron. Treatment of non-small-cell lung cancer and pharmacogenomics: where ve are and where we are going. Curr Opin Oncol. 2006, 18 (2): 135-143.
  • Camps B. Massuti, A. Jiménez, I. Maestu, R. García Gómez, D. Isla, J.L. González, D. Almenar, A. Blasco, R. Rosell, A.Carrato, N. Viñolas, N. Batista, C. García Girón, A. Galán, M. López, R. Blanco, M. Provencio, P. Diz, E.Felip. On behalf of the Spanish Lung Cancer Group Randomized Phase III Study of Three-Weekly versus Weekly Docetaxel in Pretreated Advanced Non-Small Cell Lung Cancer: A Spanish Lung Cancer Group Trial. Ann Oncol 2006 17(3): 467-472
  • de las Peñas, M. Sanchez-Ronco, V. Alberola,  M. Taron, C. Camps, R. Garcia-Carbonero, B. Massuti, C. Queralt, M. Botia, R. Garcia-Gomez, D. Isla, M. Cobo, A. Artal, M.A. Muñoz, I. Bover, D. Almenar, M.Jimenez, J. Terrasa, P. Diz, J.L. Gonzalez-Larriba, R. Barcelo, B. Medina, F. Cardenal, M. Santarpia, F.Cecere, P. Mendez, J.J. Sanchez, R. Rosell, on behalf of the Spanish Lung Cancer Group. Polymorphisms in DNA repair genes modulate survival in cisplatin-plus-Gemcitabine-Treated NSCLC. Ann Oncol 2006, 17 (4): 669-675
  • Cortes-Funes, C. Gomez, R. Rosell, P. Valero, C. Garcia-Giron, A. Velasco, A. Izquierdo, P. Diz, C.Camps, D. Castellanos, V. Alberola, F. Cardenal, J.L. Gonzalez-Larriba, JM Vieitez, I. Maeztu, JJ. Sanchez, C. Queralt, C. Mayo, P. Mendez, T. Moran , M. Taron, on behalf of the Spanish Lung Cancer Group. Epidermal Growth Factor Receptor Activating Mutations in Spanish Gefitinib-Treated Non-Small-Cell Lung Cancer Patients. Annals of Oncology, 16: 1081-1086, 2005
  • Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Maneglod C, Ono M, Queralt C, Jahan T, Sánchez JJ, Sánchez-Ronco M, Hsue V, Jablons D, Sánchez JM, Moran T. Activating Mutations in the in the Tyrosine Kinase Domain of the Epidermal Growth Factor Reseptor are associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenorcarcinomas. Clinical Cancer Research 2005; 11:5878-5885
  • Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, Sanchez JM, Nishiyama I, Moran T, Cirauqui B, Mate JL, Besse B, Reguart N, Perez M, Sanchez JJ. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer , 2005, 50, 25-33
  • Camps, E. Felip, JM. Sánchez, B. Massutí, A. Artal, L. Paz-Ares, A. Carrato, V. Alberola, A. Blasco, J: Baselga, L. Astier, M. Voi, R. Rosell. Phase II trial of the novel taxane BMS-184476 as second-line in NSCLC. Annals of Oncology, 2005 16(4) 597-601
  • Rosell, E. Felip, N. Reguart, T. Moran. Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Future Oncol.(2005) 1(3), 319-322
  • L. Ramirez ,R. Rosell, M. Taron, M. Sanchez-Ronco, V. Alberola, R.de las Peñas, J.M. Sanchez, T.Moran, C. Camps, B. Massuti, J.J. Sanchez, F. Salazar, S. Catot, on behalf of the Spanish Lung Cancer Group. 14–3–3s methylation in pre-treatment serum circulating DNA of cisplatin plus gemcitabine-treated non-small-cell lung cancer patients predicts survival. JCO. Vol. 23, nº 30: 9105-9112, desember, 2005
  • Rosell, M. Cobo, D. Isla, J.M. Sánchez, M. Taron, G. Altavilla, M Santarpia, T. Moran, O. Etxaniz. Applications of genomics in NSCLC. Lung Cancer, 49 Suppl. (2005) 33-40.
  • Rosell R, Taron M, Ariza A, Barnadas A, Mate JL, Reguart M, Margeli M, Felip E, Mendez P, Garcia-Campelo R. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004;31:20-27 (Suppl 1)
  • Rosell R. Towards customized trastuzumab in HER-2/neu-overexpresseing non-small-cell lung cancers. J Clin Oncol 2004;22:1-3 (Editorial)
  • Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004;10:1318-1325
  • Rosell R, Sanchez JM, Taron M, Moran T, Canela M, Ciuraqui B, Felip E, Massuti B, Camps C. Pemetrexed in previously treated non-small-cell lung cancer. Oncology 2004;18(suppl 5):63-71
  • Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, Queralt C, Sanchez JJ, Maestre J. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004;10 (suppl):4215s-4219s
  • Alberola V, Sarries C, Rosell R, Taron M, de las Peñas R, Camps C, Massuti B, Insa A, Garcia-Gomez R, Isla D, Artal A, Muñoz MA, Cobo M, Bover I, Gonzalez-Larriba JL, Terrasa J, Almenar D, Barcelo R, Diz P, Sanchez-Ronco M, Sanchez JJ. Effect of the methylenetetrahydrofolate C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer patients. Clin Lung Cancer 2004;5:360-365
  • Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nuñez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A,Medina B, Aartal A, Lianes P. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology 2004;15:1194-1203
  • Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Sanchez Ronco M, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Gen 2004;13:2443-2449
  • Artal-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, Camps C, Garcia-Giron C, Font A, Maestu I, Cambell J, Rosell R on behalf fo he Spanish Lung Cancer Group. Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 2004;6:175-183
  • Rosell R, Felip E, Garcia-Campelo R, Balaña C. The biology of non-small-cell lung cancer: Identifying new targets for rational therapy. Lung Cancer, vol. 46, issue 2, pp 135-148, Nov. 2004
  • Rosell R, Taron M, Sanchez JM, Moran T, Scagliotti G, Isla D, Massuti B, Alberola V, Sanchez JJ. The promise of pharmacogenomics: GEMZAR and ALIMTA. Oncology 2004 Nov; 18 (Suppl 8): 70-6
  • Rosell R, Alberola V, Taron M, Sanchez JM on behalf of the Spanish Lung Cancer Group. New approaches to lung cancer treatment. Current Oncology Reports, Dec 6, Suppl 1: S 16-17
  • Camps C, Sàrries C, Roig B, Sánchez JJ, Queralt C, Sancho, E, Martínez N, Taron M, Rosell R. Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin-Treated Locally Advanced NSCLC patients. Clinical Lung Cancer, vol 4 nº 4, 237-241, 2003
  • Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C, Bover I, Ruiz-Casado A, Azagra P, Jiménez U, González-Larriba JL, Diz P, Cardenal F, Artal A, Carrato A, Morales S, Sánchez JJ, de las Peñas R, Felip E, López-Vivanco G. Cisplatin/Gemcitabine versus a Cisplatine-Bases Triplet versys Non-Platinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A spanish Lung Cancer Group Phase III Randomized Trial. Journal of clinical Oncology, Vol 21 Nº 17 (september 1), 2003: pp 3207-3213
  • Rosell R, Taron M, Alberola V, Massutí B, Felip E, Spanish Lung Cancer Group. Genetic testing for chemotherapy in non-small-cell lung cancer. Lung Cancer vol. 41 ; 97-102 (2003)
  • Ramirez JL, Sàrries C, López de Castro P, Roig B, Queralt C, Escuin D, de Aguirre I, Sánchez JM, Manzano JL, Margelí M, Sánchez JJ, Astudillo J, Taron M, Rosell R. Methylation Patterns and K-ras Mutations in Tumor and Paired Serum of Resected NSCLC patients. Cancer Letters, vol. 193, Issue 2. 207-216 (April 2003
  • Rosell R, Taron M, Barnadas A, Scagliotti G, Sarries C, Roig B. Nucleotide Excision Repair Pathways involved in Cisplatin Resistance in NSCLC. Cancer Control, Jul/August 2003, Vol 10 Nº 4: 297-30
  • Felip E, Rosell R, Dómine M, Santomé L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañé JM, Baselga J, on the behalf of the SLCG. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage SCLC: a SLCG phase II study. Annals of Oncology Vol 14 Nº 10: 1549-1554, october 2003
  • Rosell R, Crino L, Danenberg K, Scagliotti G, Bepler G, Taron M, Alberola M, Provencio M; Camps C, De Marinis F, Sánchez JJ, de las Peñas R. Targeted Therapy in combination with Gemcitabine in Non-Small Cell Lung Cancer. Seminars in Oncology, Vol 30 nº 4 Suppl 10 (August), 2003 pp 19-25
  • Cardenal F, Dómine M, Massutí B, CArrato A, Felip E, Garrido P, Juan O, ARtal A, Barneto I, López-Vivanco G, Balcells M, Rosell R. Three-week schedule of ironotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer, vol. 39/2, 201-207, 2003
  • Rosell R, Taron M, Sàrries C, Queralt C, Roig B. B-tubulin mutational analysis: tantalizing findings. Lung Cancer, Letter to the Editor Vol 38 Issue 1 (october, 2002); 99-100
  • Rosell R, Lord Reginald VN, Taron M, Reguart N. DNA repair and cisplatin resistance in NSCLC. Lung Cancer, vol 38 issue 3: 217-227 (Des. 02
  • Rosell R, on the behalf of the Spanish Lung Cancer Group, Fossella F, Milas F. Molecular markets and targeted therapy with novel agents: prospects in the treatment of NSCLC. Lung Cancer, vol 38, supl. 4, 43-49 (Des. 02
  • Sàrries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell R. Pharmacogenomic strategies for developing customized chemotherapy in NSCLC. Pharmacogenomics (2002) 3 (6), 763-780
  • Sánchez, JM, Balañá C, Font A, Sánchez JJ, Manzano JL, Guillot M, Margelí M, Richardet M, Rosell R. Phase II non-randomized study of three diferent sequences of docetaxel and vinorelbine in patients with advanced NSCLC. Lung Cancer , vol 38, issue 3, 309-315 (Des.02)
  • Reginald V. N. Lord, Jan Brabender, David Gandara, Vicente Alberola, Carlos Camps, Manuel Domine, Felip Cardenal, José M. Sánchez, Paul H. Gumerlock, Miquel Tarón, José J. Sánchez, Kathleen D. Danenberg, Peter V. Danenberg and Rafael Rosell. Low ERCC1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer. Clinical Cancer Research Vol. 8, 2286-2291, July 2002.
  • Monzo M, Taron M, Rosell M. Genetic Analysis of the B-tubulin Gene, TUBB in NSCLC, Journal of the National Cancer Institute, Vol. 94 nº 10, 774-777, May 15, 2002
  • Rosell R, Garzemeier U, Betticher DC, Kepppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. Phase III randomised trial comparing paclitaxel/carboplatin with paclitasel/cisplatin in patients with advanced NSCLC: a cooperative multinational trial. Annals of Oncology 13:1539-1549, 2002
  • Isla D, Rosell R, Sánchez JJ, Carrato A, Felip E, Camps C, Artal A, González-Larriba JL, Azagra P, Alberola V, Martin C, Massutí B; Spanish Lung Cancer Group. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2001 Feb 15;19(4):1071-7.
  • Sacristán JA, Kennedy-Martin T, Rosell R, Cardenal F, Antón A, Lomas M, Alberola V, Massuti B, Carrato A, Minshall M. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer. 2000 May;28(2):97-107
  • Felip E, Rosell R, Alberola V, Gómez-Codina J, Maestre J, Astudillo J, Camps C, Gonzalez-Larriba JL, Moreno I, Paredes A, Artal A, García-Gómez R, Garrido P, Cardenal F, Barneto I, Sánchez JJ. Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial. Clin Lung Cancer. 2000 May;1(4):287-93.
  • Rosell R, Gómez-Codina J, Camps C, Javier Sánchez J, Maestre J, Padilla J, Cantó A, Abad A, Roig J. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999 Oct;26(1):7-14.
  • Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.
  • Antón A, Díaz-Fernández N, González Larriba JL, Vadell C, Masutti B, Montalar J, Barneto I, Artal A, Rosell R. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 1998 Nov;22(2):139-48.
  • Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.
  • Carrato A, Rosell R, Camps C, Antón A, García-Gómez R, Aranda E, Massutí B, Díaz-Fernández N, Sánchez JJ, García-Paredes ML. Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer. 1997 Jul;17(2-3):261-9.
  • Felip E, Massuti B, Camps C, Benito D, Isla D, González-Larriba JL, López-Cabrerizo MP, Salamanca O, Puerto-Pica J, Moyano A, Baselga J, Rosell R. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials. Clin Cancer Res. 1998 Nov;4(11):2723-8.
  • Salazar F, Molina MA, Sanchez Ronco M, Moran T, Ramirez JL; Sanchez J.M, Stahel R., Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo J.M, Sanchez J.J, Taron M, Rosell R. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.)
  • Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó A, Mate JL, Li S, Roig J, Olazábal A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994 Jan 20;330(3):153-8.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Puede consultar en el enlace nuestra POLÍTICA DE COOKIES, con instrucciones sobre como desactivar las cookies en su navegador en caso de así necesitarlo. Si cierra este mensaje pulsando el botón aceptar y continúa navegando está dando su consentimiento para su uso. MÁS INFORMACIÓN.

ACEPTAR

Pin It on Pinterest